Comparison 1. G‐CSF/GM‐CSF versus control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	11	2221	Peto Odds Ratio (95% CI)	0.97 [0.87, 1.09]
2 Freedom from treatment failure	6	718	Peto Odds Ratio (95% CI)	1.11 [0.91, 1.35]
3 Neutropenia	8	1013	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.60, 0.73]
4 Febrile Neutropenia, ANC < 1000	5	360	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.62, 0.89]
5 Febrile Neutropenia, ANC < 500	3	604	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.48, 0.72]
6 Infection	11	1292	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.64, 0.85]
7 Parenteral antibiotic treatment	4	359	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.57, 1.18]
8 Overall mortality during chemotherapy	11	1170	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.60, 1.43]
9 Infection related mortality during chemotherapy	12	1835	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.51, 1.71]
10 Complete response	13	2368	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.95, 1.10]
11 Adverse events: bone pain	9	1204	Risk Ratio (M‐H, Fixed, 95% CI)	3.57 [2.09, 6.12]
12 Adverse events: thrombosis and related complications (TIA, MI, cerebral non‐hemorhagic infarction)	5	425	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.56, 3.01]
13 Adverse events: skin rash	2	232	Risk Ratio (M‐H, Fixed, 95% CI)	7.69 [2.84, 20.82]
14 Adverse events: injection site reaction	2	337	Risk Ratio (M‐H, Fixed, 95% CI)	6.55 [3.01, 14.25]
15 Adverse events: myalgia	2	232	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.60, 1.45]
16 Adverse events: mucositis	4	696	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.64, 1.41]
17 Adverse events: headache	2		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
18 Withdrawals due to adverse events	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
18.1 GM‐CSF	2	228	Risk Ratio (M‐H, Fixed, 95% CI)	4.97 [2.07, 11.96]